Zosano Pharma Corporation (ZSAN)

Trade ZSAN now with
10/21/2020 8:32:29 AM Zosano Receives Complete Response Letter From FDA For Qtrypta
6/13/2020 9:21:43 AM Zosano Pharma Presents New Post-hoc Efficacy Analyses Of Qtrypta For The Acute Treatment Of Migraine
3/5/2020 8:17:04 AM Zosano Pharma Plans 11 Mln Direct Offering
2/12/2020 8:25:15 AM Zosano Pharma Reports Pricing Of $8.0 Mln Public Offering Of Common Stock And Warrants
12/23/2019 8:10:31 AM Zosano Pharma Submits 505(b)(2) NDA For Qtrypta To FDA
9/18/2019 8:31:55 AM Zosano Pharma Names Dushyant Pathak As SVP Of Business Development
7/15/2019 6:04:37 AM Zosano Presents Migraine-ACT Scores For Qtrypta Therapy Used Over 6-12 Months
1/16/2019 8:34:20 AM Zosano Appoints Linda Grais To Board